The oxidative pentose phosphate pathway (PPP) is crucial for cancer cell metabolism and tumor growth. We recently reported that targeting a key oxidative PPP enzyme, 6-phosphogluconate dehydrogenase (6PGD), using our novel small-molecule 6PGD inhibitors Physcion and its derivative S3, shows anticancer effects. Notably, humans with genetic deficiency of either 6PGD or another oxidative PPP enzyme, glucose-6-phosphate dehydrogenase, exhibit non-immune hemolytic anemia upon exposure to aspirin and various antimalarial drugs. Inspired by these clinical observations, we examined the anticancer potential of combined treatment with 6PGD inhibitors and antimalarial drugs. We found that stable knockdown of 6PGD sensitizes leukemia cells to antimalarial agent dihydroartemisinin (DHA). Combined treatment with DHA and Physcion activates AMP-activated protein kinase, leading to synergistic inhibition of human leukemia cell viability. Moreover, our combined therapy synergistically attenuates tumor growth in xenograft nude mice injected with human K562 leukemia cells and cell viability of primary leukemia cells from human patients, but shows minimal toxicity to normal hematopoietic cells in mice as well as red blood cells and mononucleocytes from healthy human donors. Our findings reveal the potential for combined therapy using optimized doses of Physcion and DHA as a novel antileukemia treatment without inducing hemolysis.
INTRODUCTION
Glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) are the first and third enzymes of the oxidative pentose phosphate pathway (PPP), which links glycolysis to anabolic biosynthesis and produces NADPH to regulate redox status in mammalian cells. Inhibition of G6PD results in attenuated cell growth as well as H 2 O 2 -mediated cell death, likely due to lack of reducing power in the form of NADPH. 1 We recently reported that 6PGD coordinates anabolic biosynthesis and redox homeostasis in cancer cells, providing a proliferative advantage to tumor cells. 2 Furthermore, we identified and developed novel, selective small-molecule 6PGD inhibitors, Physcion and its derivative S3, which demonstrate promising efficacy and minimal non-specific toxicity in inhibition of cancer cell proliferation and tumor growth in vitro and in vivo, respectively, as well as in treatment of human primary leukemia cells from leukemia patients.
2 G6PD deficiency is the most common human enzyme defect, affecting more than 400 million people worldwide. 3 Individuals with G6PD deficiency exhibit non-immune hemolytic anemia with acute hemolysis, characterized by abnormal red blood cell (RBC) breakdown in response to infection, consumption of broad beans or exposure to certain medications including aspirin and most antimalarial drugs. In addition, 6PGD deficiency has recently been identified in a Spanish family and an Italian family, with afflicted individuals exhibiting chronic hemolytic anemia. 4, 5 However, little is understood regarding the molecular mechanisms underlying the chemical induction of hemolytic anemia in 6PGD-deficient patients. Inspired by these clinical observations, together with the notion that like RBCs, tumor/leukemia cells are highly glycolytic, we tested the hypothesis that there may exist an appropriate dosing window within which combined treatment with our novel, selective 6PGD inhibitors 2 and antimalarial drugs may result in synergistic inhibition of leukemia cell proliferation without perturbing the viability of RBCs and inducing hemolytic anemia.
RESULTS

Targeting 6PGD and G6PD sensitizes human leukemia cells to antimalarial agent dihydroartemisinin
We began by testing combined treatment with Physcion+dihy-droartemisinin (DHA) in BCR-ABL-positive K562 human leukemia cells. Physcion selectively inhibits 6PGD but not G6PD ( Figure 1a ) and attenuates K562 cell proliferation in a dose-dependent manner ( Figure 1b) . We chose to focus on the antimalarial agent DHA due to its high therapeutic efficacy and safety profile in humans, which also inhibits K562 cell proliferation in a dose-dependent manner ( Figure 1c ). We first determined whether deficiency of 6PGD or G6PD in K562 cells would increase sensitivity to DHA treatment. Indeed, we found that stable knockdown of 6PGD and G6PD Combined treatment with 6PGD inhibitor Physcion+DHA synergistically inhibits human leukemia cells through AMPK activation We next explored the molecular mechanisms by which the combined therapy synergistically inhibits leukemia cell proliferation. RBCs predominantly rely on glycolysis for carbohydrate metabolism, similar to cancer cells, and the oxidative PPP is the only pathway for RBCs to produce NADPH. The current explanation of the chemical induction of hemolytic anemia in G6PD or 6PGD-deficient patients suggests that defects in the oxidative PPP due to G6PD or 6PGD deficiency result in decreased NADPH production and subsequently insufficient reductive power to maintain appropriate redox homeostasis; this in turn sensitizes RBCs to chemically induced oxidative damage by medications such as aspirin and antimalarials, which ultimately has profound effects on erythrocyte viability. 3 However, we found that, although Physcion+DHA treatment causes a significant increase in reactive oxygen species (ROS) level in K562 cells compared with cells treated with single agents (Figure 3a) , which is reversed by treatment with an antioxidant agent N-acetylcysteine (NAC) (Figure 3b ), NAC does not rescue reduced K562 cell viability by Physcion+DHA (Figure 3c ). In addition, we also tested another usual suspect, cyclooxygenase-2 (COX2), since both DHA and chloroquine have been reported to inhibit gene expression of COX2 in cancer cells 6, 7 and COX2 is expressed in most cancer cells with gradually increased levels during malignant development. However, Physcion+DHA treatment did not significantly alter the mRNA and protein expression levels of COX2 in K562 cells (Figure 3d ), while combined treatment with Physcion and COX2 inhibitor Celecoxib did not result in synergistic inhibition of K562 cell proliferation (Figure 3e ). These results suggest that combined treatment with Physcion+DHA does not inhibit leukemia cell viability by inducing oxidative damage or inhibiting COX2 expression or activity.
We next sought to test whether Physcion+DHA treatment signals through AMPK. AMPK is a master regulator of cellular energy homeostasis and is activated in response to stresses that deplete cellular ATP supplies such as low glucose and hypoxia. AMPK activation may lead to autophagy or apoptosis, depending on the environmental nutrient availability. Anticancer effects of AMPK activation have been well documented 8 and AMPK activators including A769662 have been shown to be effective as anticancer agents in a number of cancer cell types, including human prostate cancer cells 9 and human breast cancer cells. 10, 11 Recently, both aspirin and chloroquine treatments were reported to promote phosphorylation and activation of AMPK. 10, 11 We also reported that 6PGD regulates the intracellular level of its product Ru-5-P to inhibit LKB-AMPK signaling, and treatment with 6PGD inhibitor Physcion results in activation of AMPK. 2 Indeed, we found that treatment with Physcion+DHA effectively activates AMPK as assessed by increased T172 phosphorylation level of AMPK. Furthermore, we also found that NAC treatment does not abrogate the synergistic activation of AMPK seen in Physcion +DHA-treated cells (Supplementary Figure S1 ). ACC1 plays a key role in fatty acid synthesis, where its major function is to synthesize malonyl-CoA as a substrate for de novo lipid synthesis, a critical metabolic process for proliferating cells. Phosphorylation of ACC1 at S79 by AMPK inhibits ACC1 enzyme activity, 12 leading to decreased lipid biosynthesis and cell proliferation. 13 To further delineate the pathway through which Physcion+DHA signal to inhibit leukemia cell proliferation, we assessed phosphorylation of AMPK substrate acetyl-CoA carboxylase 1 (ACC1). As expected, we found that phosphorylation of ACC1 follows the activation pattern of AMPK ( Figure 5c ). Furthermore, we previously demonstrated that 6PGD-mediated production of ribulose-5-phosphate (Ru-5-P) inhibits AMPK activation by disrupting the active LKB1 complex. 2 In consonance with this, we found decreased Ru-5-P level as well as increased LKB1 kinase activity in K562 cells with combined drug treatment (Supplementary Figure S2A) . In addition, in a control experiment, DHA+Physcion treatment of cells with stable knockdown of CaMKK2, an alternative upstream kinase of AMPK, display increased phosphorylation of AMPK and ACC1, while increased phosphorylation was predominantly abolished in LKB1 knockout cells treated with Physcion+DHA (Supplementary Figures S2B and C). Taken together, our data suggest that LKB1 is the relevant upstream activator of AMPK with combined drug treatment and the effect of Physcion+DHA is predominantly mediated through Ru-5-P dependent regulation of LKB1 in cells. Combined treatment with 6PGD inhibitor and DHA inhibits tumor growth of human leukemia cells in xenograft nude mice We previously showed that treatment with Physcion derivative S3 shows minimal toxicity to human cells in vitro and is well tolerated with minimal toxicity in nude mice (20 mg/kg/day for 30 days), and that 20 mg/kg/day was efficacious to inhibit tumor growth in xenograft nude mice injected with human cancer cells including K562 leukemia cells. 2 However, the principal concern in considering the feasibility of Physcion+DHA combination treatment as an anticancer therapy is its potential to induce hemolysis at the whole organism level. To address this concern, we performed chronic toxicity studies by injecting S3+DHA into nude mice for 30 days. We found that 5 mg/kg/day S3+2.5 mg/kg/day DHA administered intraperitoneally is a well-tolerated dose, and did not significantly alter body weight (data not shown) of nude mice. Importantly, we observed that this dose of S3+DHA did not significantly affect the hematopoietic properties of nude mice, and that both hemoglobin (Hb) and RBC levels fell within the normal range, suggesting no evidence of RBC damage (Table 1 ). These results demonstrate that S3+DHA combination treatment at such doses has minimal toxicity in vivo. To determine whether such doses of S3 and DHA are sufficient to inhibit tumor growth in vivo, we next performed in vivo drug treatment using a xenograft model in which nude mice were subcutaneously injected with K562 cells on the right flank. Three days post-injection, mice were randomly divided into four groups and treated with dimethyl sulfoxide (DMSO), S3 (5 mg/kg/day), DHA (2.5 mg/kg/day) or S3+DHA (5 mg/kg/day+2.5 mg/kg/day) for 15 days. We found that S3+DHA treatment did not cause any noticeable damage to diverse organs and tissues, nor to the overall morphology or composition of the bone marrow (Figure 6a Combination therapy inhibits cell viability of primary human leukemia cells with minimal toxicity Lastly, we found that Physcion+DHA treatment significantly inhibited viability of primary leukemia cells from representative patients with diverse types and subtypes of leukemia (Figure 7a ), including the acute promyelocytic leukemia subtype of acute myeloid leukemia, acute myeloid leukemia and chronic myeloid leukemia. Moreover, Physcion+DHA treatment resulted in increased levels of phospho-AMPK compared with DMSO, Physcion or DHA treated primary leukemia cells from a representative acute myeloid leukemia patient (Figure 7b ). In contrast, despite increased AMPK phosphorylation induced by Physcion+DHA treatment in mononucleocytes (WBC) isolated from the PB of healthy human donors (Supplementary Figures  S4A and B) , neither drug alone nor the combination affected AMPK phosphorylation in RBC cells (Supplementary Figure S4C) or cell viability of WBC or RBCs isolated from the PB of healthy human donors (Figure 7c and Supplementary Figures S4D and E) , suggesting promising antileukemia potential with minimal toxicity to human blood cells.
DISCUSSION
Taken together, inspired by the clinical observations in hemolytic anemia patients with G6PD or 6PGD deficiency, we developed a novel therapeutic strategy and provide 'proof of principle' to suggest that combining 6PGD inhibitors with antimalarial agent DHA is a promising antileukemia therapy. Most importantly, although deficiency of oxidative PPP enzymes G6PD and 6PGD renders red blood cells in human patients sensitive to treatment with antimalarial agents, we propose that because leukemia cells might be rewired by leukemogenic signals to become 'addicted' to certain signaling and metabolic processes such as attenuated LKB1-AMPK pathway, we are able to determine a dosing window in which we can inhibit 6PGD at a concentration that renders leukemia cells, but not normal cells, sensitive to antimalarial treatment, which synergistically activates LKB-AMPK signaling. This is supported by the results showing that, although Physcion +DHA treatment resulted in increased AMPK phosphorylation in both normal WBCs from healthy donors and primary leukemia cells from patients, only the primary leukemia cells responded to the combined treatment with reduced cell viability ( Figure 7 and Supplementary Figure S4) .
Our studies also suggest that G6PD and 6GPD, although both similarly implicated in hemolytic anemia, signal differentially in leukemia cells to promote cell viability. We found that, while G6PD and 6PGD-deficient cells were similarly sensitive to DHA treatment (Figure 1f and Supplementary Figures S3A) , the decreased cell viability in G6PD-deficient cells could not be rescued by AMPK inhibition (Supplementary Figures S3B and C) . Together, these findings demonstrate that, unlike 6PGD, sensitivity to DHA in G6PD knockdown cells may be regulated in an AMPK-independent manner. These data are also consistent with our previous work, which shows that AMPK phosphorylation as well as cell proliferation rate remain unaltered in G6PD knockdown cells 2 (Supplementary Figure S8C) . Moreover, these results suggest differential molecular mechanisms underlying the sensitivity of G6PD-deficient hemolytic anemia patients to DHA or other antimalarial agents compared with 6PGD-deficient patients.
Further studies are warranted to fully decipher the mechanisms underlying distinct enzymes in the oxidative PPP in cancer cell proliferation and survival, and to explore the potential involvement of AMPK activation in hemolysis induced by food (fava beans) and chemicals (aspirin and many antimalarial agents) in individuals with genetic deficiency of 6PGD, which may inform improved treatment strategies for these patients.
MATERIALS AND METHODS
Cell lines
All cell lines were originally obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and their identity was authenticated by Short Tandem Repeat (STR) profiling.
Reagents
Stable KD of endogenous h6PGD was achieved using lentiviral vector harboring shRNA construct (Open Biosystems, Lafayette, CO, USA; 5′-CCGGGTGGATGATTTCATCGAGAAACTCGAGTTTCTCGATGAAATCATCCACTT TTT-3′). The shRNA is designed to target the 3' non-coding region of h6PGD-A mRNA and shows no effect on the plasmid directed expression of 6PGD cDNA in cells. Stable KD of endogenous hG6PD was achieved using lentiviral vector harboring shRNA construct (Open Biosystems; 5′-CCGGCCCTGAAGTGACTGAGACAATCTCGAGATTGTCTCAGTCACTTCAGGGT Nude mice were treated with vehicle control, S3 alone (5 mg/kg/day), DHA alone (2.5 mg/kg/day) or S3+DHA for 30 days. CBC analysis shows no significant difference in the hematopoietic properties among the four groups of mice.
TTTT-3′). Stable KD of endogenous hAMPK was achieved using lentiviral vector harboring shRNA construct (Open Biosystems; 5′-CCGGGCAT AATAAGTCACAGCCAAACTCGAGTTTGGCTGTGACTTATTATGCTTTTT-3′). Antibodies against AMPK (cat# 5831), phospho-AMPK (T172) (cat# 2535), ACC1 (cat# 3662), phospho-ACC1 (S79) (cat# 11818), G6PD (cat# 12263) and LKB1 (cat# 3050) were from Cell Signaling Technology (CST, Danvers, MA, USA); antibody against 6PGD was from Novus (Novus Biologicals, LLC., Littleton, CO, USA) (cat# NBP1-31589); antibody against β-actin was from Sigma (Louis, MO, USA, cat# A1978); prediluted Ki67 antibody was from Invitrogen (Grand Island, NY, USA, cat# 08-0156). Physcion was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). 1-Hydroxy-8-methoxyanthraquinone (S3) was purchased from Sigma. Dehydroepiandrosterone was purchased from Calbiochem (Billerica, MA, USA). DHA was purchased from TCI America (Portland, OR, USA). A769662 was purchased from LC Laboratories (Woburn, MA, USA). Compound C was purchased from EMD Millipore (Billerica, MA, USA).
Cell culture K562, HEL, KG1a and Molm14 cells were cultured in RPMI 1640 medium with 10% fetal bovine serum and penicillin/streptomycin. K562 6PGD stable KD cells were cultured in the presence of 6 μg/ml puromycin. K562 G6PD and AMPK stable KD cells were cultured in the presence of 2 μg/ml puromycin. 
G6PD and 6PGD assays
Purified 6PGD and G6PD proteins were treated with increasing concentrations of Physcion or vehicle (DMSO) for 4 h, followed by enzyme activity assays. G6PD activity was determined by the NADPH production rate from G6PD and 6PGD, then subtracting that of 6PGD, since a product of G6PD, 6-phosphogluconolactone, is rapidly hydrolyzed to a substrate of 6PGD, 6-phosphogluconate, in cells. To obtain the combined dehydrogenase activity, substrates for both dehydrogenase enzymes were added to a cuvette. In another cuvette, substrates for the second enzyme, 6PGD, were added to obtain the activity of this enzyme. Substrate concentrations were as follows: 0.2 mM glucose-6-phosphate, 0.2 mM 6-phosphogluconate and 0.1 mM NADP + . Ten micrograms of cell lysates were added to a cuvette containing buffer (50 mM Tris/1 mM MgCl 2 , pH 8.1) and the reaction was then initiated by NADP + . The increase in 341 nm absorbance ( OD340 ) as a measure of NADPH production was measured every 20 s for 10 min on a DU800 Spectrophotometer (Beckman Coulter, Indianapolis, IN, USA).
Oxidative PPP flux assay using 14 CO 2 release
Cells were seeded on 6-cm dishes that are placed in a 10-cm dish with 2 sealed pinholes on the top. 14 CO 2 released from cells was collected by completely sealing the 10-cm dish, in which the cells on the 6-cm dish were incubated in 2 ml of medium containing [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-or [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-glucose, respectively, at a final specific activity of 10 μCi/ml glucose at 37°C for 3 h. The oxidative PPP flux was stopped by injecting 0.3 ml of 50% TCA through one of the holes on the top, and at the same time Each dish was completely re-sealed with parafilm and incubated overnight at room temperature. Hyamine hydroxide in the small cup was dissolved into 60% methanol and directly subjected to scintillation counting.
Cell viability assays 0.5 × 10 6 cells were seeded in six-well plates and incubated with indicated drug concentrations at 37°C for 36-48 h. Relative cell viability was determined by trypan blue exclusion using a TC10 Automated Cell Counter (BioRad, Hercules, CA, USA). Combination index (CI) values were calculated using ComboSyn program.
Apoptosis assay 1 × 10 5 cells were treated with indicated drug concentrations for 24 h, then collected and stained using FITC-conjugated annexin V labeling reagent (BD Pharmingen, San Diego, CA, USA) and PI (Sigma) followed by FACS analysis for apoptotic cell population.
Intracellular ROS production
The amount of intracellular ROS was measured by detecting dichlorodihydrofluorescein, which is the cleavage product of carboxy-H 2 DCFDA (Invitrogen) by ROS. 1 × 10 5 cells were seeded in a six-well plate and treated with drug at indicated concentrations. Two hours after treatment, cells were washed with PBS and loaded with 5 μM carboxy-H 2 DCFDA for 30 min. The cells were harvested, resuspended in PBS and analyzed using a FACS (BD Biosciences, San Jose, CA, USA; excitation and emission at 490 and 530 nm, respectively). P-values were determined by two-tailed Student's t-test (*0.01 oP o0.05; **0.001 oP o0.01; NS, not significant).
Lipid synthesis assay
Cells were preincubated in complete growth medium in the absence of D-(14C-U)-glucose for 2 h. Lipids were extracted by the addition of 500 μl of hexane/isopropanol (3:2 v/v), air dried, resuspended in 50 μl of chloroform and subjected to scintillation counting.
Complete blood counts
For complete blood counts, blood was collected retro-orbitally and immediately applied to a HemaVet 950FS (Drew Scientific, Miami Lakes, FL, USA) for generation of complete hematology profile.
Primary tissue samples from patients with leukemia and healthy donors Approval of use of human specimens was given by the Institutional Review Board of Emory University School of Medicine. All clinical samples were obtained with informed consent with approval by the Emory University Institutional Review Board. Clinical information for the patients was obtained from the pathologic files at Emory University Hospital under the guidelines and with approval from the Institutional Review Board of Emory University School of Medicine and according to the Health Insurance Portability and Accountability Act. Only samples from patients who were not previously treated with chemotherapy or radiation therapy were used. Mononuclear cells and RBCs were isolated from PB and bone marrow samples from patients with leukemia or from healthy donors using lymphocyte separation medium (Cellgro, Keller, TX, USA). Cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin and incubated with indicated drug concentrations for 48 h.
Xenograft studies
Approval of use of mice and designed experiments was given by the Institutional Animal Care and Use Committee of Emory University. Nude mice (nu/nu, female 4-to 6-week-old; Harlan Laboratories, Dallas, TX, USA) were subcutaneously injected with 5 × 10 6 K562 cells on the right flank. Three days after injection, mice were randomly divided into four treatment groups. Treatment was administered by daily intraperitoneal injection (S3: 5 mg/kg/day; DHA: 2.5 mg/kg/day; S3+DHA: 5+2.5 mg/kg/day). Tumor growth was recorded by measurement of two perpendicular diameters using the formula 4π/3 × (width/2) 2 × (length/2). The tumors were harvested and weighed at the experimental end point, and the masses of tumors (g) treated with vehicle control (DMSO) and drug treated groups were compared by two-way ANOVA.
Statistics
In studies in which statistical analyses were performed, a two-tailed Student's t-test was used to generate P-values. P-values less than or equal to 0.05 were considered significant. A two-way ANOVA was used for tumor volume and tumor weight. Combination indexes were calculated using CalcuSyn software, where CI = 1 indicates an additive effect, CIo 1 indicates synergism and CI41 indicates antagonism in drug combinations.
Study approval
Approval of use of human specimens was given by the Institutional Review Board (IRB) of Emory University School of Medicine, and participants were given informed consent in accordance with IRB policy.
Reproducibility of experiments
The results of one representative experiment from at least two independent experiments are shown except data obtained from primary patient samples and animal experiments shown in Figures 6 and 7 . There is no estimate of variation in each group of data and the variance is similar between the groups. No statistical method was used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. All data are expected to have normal distribution.
